Federal Register
Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus; Guidance for Industry; Availability- Facts included
- The Food and Drug Administration (FDA) is announcing the availability of a final guidance titled "Recommendations for Reducing the Risk of Transfusion‑Transmitted Hepatitis B Virus."
- The guidance provides blood establishments that collect blood and blood components, including Source Plasma, with FDA's recommendations for testing blood and blood components for hepatitis B virus (HBV) to reduce the risk of transfusion‑transmitted HBV.
- The guidance applies to the collection of Whole Blood and blood components, including Source Plasma.
- The final guidance finalizes the draft guidance titled "Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen" (July 2025 Draft Guidance).
- The guidance supersedes several prior FDA documents, including memoranda from 1987, 1991, 1996, and final guidances from 2007, 2010, 2011, and 2012.
- Sourcing
- High – the information comes directly from an official FDA notice, which is a primary source for regulatory announcements.
- Framing
- The text is purely factual reporting of an FDA announcement; it contains no opinion or editorial commentary.
- Omissions
- The announcement does not explain the specific reasons for updating the guidance at this time, such as recent changes in HBV epidemiology, advances in testing technology, or regulatory considerations. It also lacks information on how the new recommendations will be implemented…
- Rhetorical notes (3)
- Factual Reporting · Citation of Authority · Absence of Emotional Language